Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
Published Online: 2022-03-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Aurore Perrot•Franck Dubin•Fredrik Schjesvold•H Miles Prince•Helgi van de Velde•Ivan Spicka•Jeffrey Shang-Yi Huang•Jesus San-Miguel•Jiri Minarik•Kenneth C Anderson•Laure Malinge•Meletios A Dimopoulos•Meral Beksac•Michele Cavo•Paul G Richardson•Philippe Moreau•Xavier Leleu
